Prebiotic Fiber as a Modifier of Satiety Hormones and Body Weight in Overweight and Obese Adults
Effect of Oligofructose Versus Placebo on Body Weight and Satiety Hormone Secretion in Overweight and Obese Adults.
1 other identifier
interventional
48
1 country
1
Brief Summary
The purpose of this study is to determine if oligofructose supplementation promotes weight loss in overweight and obese adults.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable obesity
Started Jan 2007
Shorter than P25 for not_applicable obesity
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2007
CompletedFirst Submitted
Initial submission to the registry
August 27, 2007
CompletedFirst Posted
Study publicly available on registry
August 29, 2007
CompletedMay 23, 2008
May 1, 2008
4 months
August 27, 2007
May 21, 2008
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Body weight
3 months
Secondary Outcomes (1)
Plasma satiety hormones
3 months
Study Arms (2)
1
ACTIVE COMPARATOROligofructose
2
PLACEBO COMPARATORPlacebo
Interventions
21 grams per day in distributed over 3 doses per day for 3 months
7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months
Eligibility Criteria
You may qualify if:
- overweight or class I obese individuals with BMI between 25 kg/m2 and 34.9 kg/m2
- stable body weight in previous 3 months
You may not qualify if:
- Type 1 and Type 2 diabetes
- clinically significant cardiovascular abnormalities
- liver or pancreas disease
- major gastrointestinal surgeries
- are pregnant or lactating
- exhibit alcohol or drug dependence
- on drugs influencing appetite
- are following a diet or exercise regime designed for weight loss
- have a body mass greater than 350lb
- chronic use of antacids or bulk laxatives
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Faculty of Kinesiology, Roger Jackson Centre for Health and Wellness Research
Calgary, Alberta, T2N 1N4, Canada
Related Publications (2)
Parnell JA, Klancic T, Reimer RA. Oligofructose decreases serum lipopolysaccharide and plasminogen activator inhibitor-1 in adults with overweight/obesity. Obesity (Silver Spring). 2017 Mar;25(3):510-513. doi: 10.1002/oby.21763.
PMID: 28229548DERIVEDParnell JA, Reimer RA. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr. 2009 Jun;89(6):1751-9. doi: 10.3945/ajcn.2009.27465. Epub 2009 Apr 22.
PMID: 19386741DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Raylene A. Reimer, PhD, RD
University of Calgary
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
August 27, 2007
First Posted
August 29, 2007
Study Start
January 1, 2007
Primary Completion
May 1, 2007
Study Completion
August 1, 2007
Last Updated
May 23, 2008
Record last verified: 2008-05